8-K
Coya Therapeutics Announces Open-Label Extension for Phase 2/3 ALSTARS Trial of COYA 302 in ALS
8-K
Coya Therapeutics Announces Full Enrollment of Phase 2/3 ALSTARS Trial for COYA 302 in ALS
8-K
Coya Therapeutics Announces Enrollment of 100th Patient in Phase 2/3 ALSTARS Trial of COYA 302 for ALS
8-K
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
8-K/A
Board Appoints Mark H. Pavao to Audit Committee, Effective Immediately, Following Nominating Committee's Recommendation
8-K
Coya Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders
